Skip to main content

Drug Interactions between fostemsavir and Mavyret

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

glecaprevir fostemsavir

Applies to: Mavyret (glecaprevir / pibrentasvir) and fostemsavir

MONITOR: Coadministration with fostemsavir may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion transporting polypeptides (OATP) 1B1/1B3 and breast cancer resistance protein (BCRP). Temsavir, the active moiety of fostemsavir, is an inhibitor of OATP 1B1 and 1B3. Additionally, temsavir and two metabolites are inhibitors of BCRP. When a single 10 mg dose of rosuvastatin, an OATP 1B1/1B3 and BCRP substrate, was administered with fostemsavir 600 mg twice daily in 18 study subjects, mean rosuvastatin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 78% and 69%, respectively, compared to rosuvastatin administered alone.

MANAGEMENT: Caution is advised when fostemsavir is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostemsavir is added to or withdrawn from therapy.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2020) "Product Information. Rukobia (fostemsavir)." ViiV Healthcare
Moderate

pibrentasvir fostemsavir

Applies to: Mavyret (glecaprevir / pibrentasvir) and fostemsavir

MONITOR: Coadministration with fostemsavir may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion transporting polypeptides (OATP) 1B1/1B3 and breast cancer resistance protein (BCRP). Temsavir, the active moiety of fostemsavir, is an inhibitor of OATP 1B1 and 1B3. Additionally, temsavir and two metabolites are inhibitors of BCRP. When a single 10 mg dose of rosuvastatin, an OATP 1B1/1B3 and BCRP substrate, was administered with fostemsavir 600 mg twice daily in 18 study subjects, mean rosuvastatin peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 78% and 69%, respectively, compared to rosuvastatin administered alone.

MANAGEMENT: Caution is advised when fostemsavir is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostemsavir is added to or withdrawn from therapy.

References (3)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2020) "Product Information. Rukobia (fostemsavir)." ViiV Healthcare

Drug and food interactions

Moderate

glecaprevir food

Applies to: Mavyret (glecaprevir / pibrentasvir)

ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of glecaprevir and pibrentasvir. Relative to fasting conditions, mean glecaprevir systemic exposure (AUC) increased by 83% to 163% and mean pibrentasvir AUC increased by 40% to 53% when administered with moderate to high fat meals.

MANAGEMENT: Glecaprevir-pibrentasvir should be administered with food.

References (1)
  1. (2017) "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer